Insights Into Day One Biopharmaceuticals Inc (DAWN) Exposure By Institutions

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

Day One Biopharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Day One Biopharmaceuticals Inc is $1.24B. A total of 0.96 million shares were traded on the day, compared to an average of 979.57K shares.

In the most recent transaction, Dubow Adam sold 3,202 shares of DAWN for 14.00 per share on Aug 16 ’24. After the transaction, the GENERAL COUNSEL now owns 26,928 company shares. In a previous transaction on Aug 16 ’24, York Charles N II sold 2,633 shares at 14.00 per share. DAWN shares that COO, CFO AND SECRETARY owns now total 232,485.

Among the insiders who sold shares, Blackman Samuel C. disposed of 2,232 shares on Aug 16 ’24 at a per-share price of $14.00. This resulted in the HEAD OF R&D holding 1,127,535 shares of DAWN after the transaction. In another insider transaction, Bender Jeremy sold 10,681 shares at $14.00 per share on Aug 16 ’24. Company shares held by the CHIEF EXECUTIVE OFFICER now total 98,932.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, DAWN has a high of $18.07 and a low of $9.67.

As of this writing, DAWN has an earnings estimate of -$0.42 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of $0.3 per share and a lower estimate of -$0.79. The company reported an EPS of -$0.54 in the last quarter

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. DAWN’s latest balance sheet shows that the firm has $284.31M in Cash & Short Term Investments as of fiscal 2021. There were $220.00k in debt and $8.66M in liabilities at the time. Its Book Value Per Share was $3.50, while its Total Shareholder’s Equity was $281.15M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DAWN is Buy with a score of 4.70.

Most Popular

Related Posts